None, other than smaller more flexible funds, but aren’t worth pursuing. This is why company needs to get off OTC and do an R/S and small ongoing buyback beyond just R&D investment. Company has had to reinvent itself multiple times and is about to embark on another one April 1st without Lannett. We may not hear how that transition is being executed until August call for Q1 results.
News 
Market Data 
Discover 
